ArticleDiabetes, obesity & metabolism2026
Risk of Psychiatric Worsening With GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.Diabetes, obesity & metabolism · 2026Article
- Risk of Psychiatric Worsening With GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsTo compare 1-year psychiatric outcomes after GLP-1 receptor agonist (GLP-1 RA) versus sodium-glucose cotransporter-2 inhibitor (SGLT2i) initiation in patients with type 2 diabetes and treated depression. MATERIALS AND
methodsWe conducted a retrospective active-comparator, new-user cohort study using electronic health records from the TriNetX network. Patients with type 2 diabetes, depression and antidepressant treatment within 6 months before index were included. After 1:1 propensity score matching, outcomes were compared using Cox proportional hazards models. Primary outcomes were suicidality and antipsychotic use. All-cause mortality was a secondary outcome.
resultsAfter propensity score matching, 34 761 patients were included in each group. GLP-1 RA initiation was not associated with a higher risk of suicidality than SGLT2i initiation (hazard ratio [HR] 0.88, 95% CI 0.74-1.05). GLP-1 RA initiation was associated with a lower risk of antipsychotic use (HR 0.86, 95% CI 0.82-0.90; absolute risk difference -1.4%) and lower all-cause mortality (HR 0.64, 95% CI 0.58-0.71). Findings were consistent across sensitivity analyses.
conclusionsIn patients with type 2 diabetes and treated depression, we did not detect increased short-term documented suicidality after GLP-1 RA initiation compared with SGLT2i initiation and observed less subsequent treatment intensification. These observational findings suggest that treated depression alone should not lead to routine avoidance of GLP-1 RAs in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.